- $44.53m
- -$11.28m
- $15.30m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.78 | ||
| Price to Tang. Book | 0.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.63% | ||
| Return on Equity | -106.46% | ||
| Operating Margin | -678.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 5.88 | 11.84 | 14.52 | 15.3 | 17.57 | 20.63 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.
Directors
- Matthew Posard NEC (48)
- John Dobak CEO (55)
- Kevin Sun CFO (43)
- Claudia Ibarra COO (58)
- Ray Akhavan CCO (52)
- Loren Clarke OTH
- Todd Wood OTH (52)
- Nathalie Keraudy DRC
- Monica Tellado DRC
- Cynthia Collins IND (63)
- Enrico Picozza IND (61)
- Herman Rosenman IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 27th, 2019
- Public Since
- June 20th, 2017
- No. of Shareholders
- 163
- No. of Employees
- 206
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 69,148,120
- Address
- 12340 EL CAMINO REAL, SAN DIEGO, 92130
- Web
- Phone
- +1 8584504222
- Auditors
- KPMG LLP
Latest News for DMTK
Upcoming Events for DMTK
Q1 2024 DermTech Inc Earnings Release
DermTech Inc Annual Shareholders Meeting
Q2 2024 DermTech Inc Earnings Release
Similar to DMTK
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 19:06 UTC, shares in DermTech are trading at $0.64. This share price information is delayed by 15 minutes.
Shares in DermTech last closed at $0.64 and the price had moved by -83.82% over the past 365 days. In terms of relative price strength the DermTech share price has underperformed the S&P500 Index by -86.53% over the past year.
The overall consensus recommendation for DermTech is Hold. You can view the full broker recommendation list by unlocking its StockReport.
DermTech does not currently pay a dividend.
DermTech does not currently pay a dividend.
DermTech does not currently pay a dividend.
To buy shares in DermTech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.64, shares in DermTech had a market capitalisation of $44.53m.
Here are the trading details for DermTech:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DMTK
Based on an overall assessment of its quality, value and momentum DermTech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in DermTech is $2.04. That is 216.77% above the last closing price of $0.64.
Analysts covering DermTech currently have a consensus Earnings Per Share (EPS) forecast of -$2.13 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DermTech. Over the past six months, its share price has underperformed the S&P500 Index by -58.26%.
As of the last closing price of $0.64, shares in DermTech were trading -60.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The DermTech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
DermTech's management team is headed by:
- Matthew Posard - NEC
- John Dobak - CEO
- Kevin Sun - CFO
- Claudia Ibarra - COO
- Ray Akhavan - CCO
- Loren Clarke - OTH
- Todd Wood - OTH
- Nathalie Keraudy - DRC
- Monica Tellado - DRC
- Cynthia Collins - IND
- Enrico Picozza - IND
- Herman Rosenman - IND